Baxter International Inc. · Baxter is a leading provider of immunoglobulin therapies for patients...

Baxter International Inc.

BAX_CorpBR11_3.06.indd 1 3/7/12 8:45 AM

About our Cover:

Kanyakorn Piasukho of Bangkok, Thailand, was diagnosed with

chronic nephritis in infancy and experienced acute kidney failure

in 2009. She relies on Baxter peritoneal dialysis products as she

awaits a possible kidney transplant.

BAX_CorpBR11_3.06.indd 2 3/6/12 5:02 PM

1

Baxter International Inc. innovates, develops, manufactures

and markets products for people with hemophilia, immune

disorders, infectious diseases, kidney disease, trauma, and

other chronic and acute medical conditions. The company’s

diverse portfolio is focused on treatments that save and sustain

lives. As a global, diversified healthcare company, Baxter

applies a unique combination of expertise in medical devices,

pharmaceuticals and biotechnology to research and create

products that advance patient care worldwide.

Baxter International Inc.


2

Worldwide Presence

Thomas Polzer, research scientist at Baxter’s Orth, Austria, facility, conducts validation experiments on the company’s investigational recombinant factor IX product for patients with hemophilia B.


3


4

A Pioneer in Healthcare Baxter has been a healthcare leader for more than 80 years with a rich history of medical “firsts.” The company was responsible for the first commercially manufactured intravenous (IV) solutions, the first commercial kidney dialysis system, the first factor VIII concentrate to treat hemophilia and many other medical breakthroughs. More recent firsts include the first recombinant factor VIII processed with no blood-based additives and the first cell culture-derived pandemic influenza vaccine.

Life-Saving ProductsBaxter products are infused, injected or inhaled more than two billion times annually (or six million times a day), each time to treat a life-threatening acute or chronic condition. Patients with hemophilia, end-stage kidney disease, primary immune deficiency and a range of other diseases depend on Baxter products. This creates a common purpose among Baxter’s approximately 48,500 employees worldwide: to save and sustain lives.

Innovation is the driving force

behind Baxter’s success. The

company is a technology leader in

recombinant and plasma-derived

therapeutic proteins, IV and

dialysis solutions and devices,

drug delivery systems, and

other technologies.

Worldwide Presence

Ten-year-old Brenden Broyles of Denver, Colorado, a primary immunodeficiency patient, was a participant in Baxter’s clinical trial of an investigational therapy designed to provide subcutaneous infusion of immune globulin through a single injection site at volumes, intervals and rates comparable to intravenous infusion.


5

Scientific Capabilities Innovation is the driving force behind Baxter’s success. The company is a technology leader in the research and development of recombinant and plasma-derived therapeutic proteins, IV and dialysis solutions and devices, drug packaging and delivery systems, and other technologies. Baxter’s businesses share expertise in medical plastics, biologics, sterilization and other scientific disciplines to create a range of life-saving products.

Global Scope Baxter products are sold in more than 100 countries, with approximately 60 percent of the company’s revenues coming from outside the United States. Baxter’s greatest growth opportunities are in developing and emerging markets, where many people with life-threatening conditions are under-treated. As the economies of these countries continue to develop, Baxter is poised to meet their healthcare needs.

Manufacturing StrengthBaxter’s manufacturing strength and commitment to quality are foundations of the company. With more than 50 production facilities in 27 countries, proprietary technologies, and complementary manufacturing platforms across its businesses, Baxter can produce high-quality products cost-effectively for local and regional markets, helping improve healthcare quality worldwide.

A Socially Responsible CitizenPart of being a great company is being a responsible corporate citizen. Baxter gives back to the communities it serves through environmental stewardship, employee volunteerism, corporate giving and other initiatives. Baxter has been recognized for its commitment to sustainability, the company’s long-term strategic approach to including social, economic and environmental considerations and opportunities to achieve its business objectives and contribute to a more sustainable world.

Simone von Fircks (left), research and development senior manager, and Irene Kinzl, research scientist, use state of the art imaging technology to select cells used in Baxter therapies at the company’s Orth, Austria, facility.

Children in the Campo Limpo region of São Paulo, Brazil, receive dental care and education thanks to Projeto Arrastão, a recipient of a grant from The Baxter International Foundation.


6

Moris de Boer of Rotterdam, the Netherlands, has multifocal motor neuropathy (MMN), a chronic disease characterized by progressive weakness in the limbs. Baxter produces the only centrally licensed treatment across the European Union for MMN.


7

BioScience

Baxter’s BioScience business develops recombinant and plasma-

based proteins to treat hemophilia and other bleeding disorders;

plasma-based therapies to treat immune deficiencies, alpha-1

antitrypsin deficiency, burns and shock, and other blood-related

conditions; products for regenerative medicine, such as proteins

used to promote hemostasis and wound-sealing in surgery; and

selected vaccines.

In 1941, Baxter introduced the first system for separating plasma

from whole blood and storing it for later use. Plasma contains a

number of proteins that serve various therapeutic purposes. The

company later became a leader in plasma fractionation – the

process of breaking down plasma into its component parts – to

produce a range of plasma-derived therapeutic proteins. In the

1990s, Baxter added recombinant technology to its capabilities,

enabling the company to produce some therapeutic proteins, such

as factor VIII for hemophilia, in cell culture rather than through

plasma fractionation. Baxter’s BioScience business continues to

advance medical science to research and develop new and better

life-saving products and therapies for patients.


8

HemophiliaBaxter is a leading developer of clotting factors to treat hemophilia. This includes recombinant and plasma-based factor VIII – the clotting protein missing from the blood of people with hemophilia A – and therapies for people that develop inhibitors against clotting factor. Baxter also has a number of research and development programs aimed at improving the treatment of hemophilia and other bleeding disorders. These include a longer-acting (PEGylated) form of a full-length recombinant factor VIII protein, recombinant factor IX therapy for hemophilia B, a recombinant therapy for inhibitor patients and the first recombinant therapy for von Willebrand disease.

In 2011, Gilberto Jiménez Chávez of Mexico City experienced extreme bleeding during surgery to remove a brain tumor. Surgeons used a Baxter-produced hemostatic matrix to help control the bleeding.

Baxter’s BioScience business

continues to advance medical

science to develop new and

better life-saving products and

therapies for patients.

BioScience


9

BioTherapeuticsBaxter is a leading provider of immunoglobulin therapies for patients with immune deficiencies. These plasma-derived therapies provide antibody replacement for patients whose immune systems do not produce enough antibodies to fight infection. In addition to primary immunodeficiency, the therapy also is being investigated for use in neurological conditions, such as Alzheimer’s disease. In Europe, the therapy has been approved to treat multifocal motor neuropathy, a degenerative disease that attacks the peripheral nerves, resulting in progressive limb weakness. Other products include albumin, a plasma-volume expander used to treat burns and maintain adequate fluid volume in critical care patients, and alpha1-proteinase inhibitor to treat alpha-1 antitrypsin deficiency, a respiratory condition that can result in early onset emphysema.

BioSurgeryIn recent years, Baxter has attained technological leadership in the research and development of biosurgery products – biological and chemical products used to stop bleeding and seal wounds in surgery – and technologies to facilitate hard tissue regeneration in orthobiologics and soft tissue repair used in a variety of surgical procedures. The company’s stem cell technologies are being explored for their potential to restore blood flow in patients with cardiovascular and peripheral artery disease.

VaccinesBaxter provides vaccines for meningitis C, tick-borne encephalitis, and seasonal and pandemic influenza. Baxter’s Vero cell technology, used in flu vaccine production, offers potential advantages over traditional egg-based vaccine production methods.

FDA approval of a prophylaxis indication for a Baxter recombinant factor VIII treatment for hemophilia A supports patients like Jay Brown of Baton Rouge, Louisiana, in infusing treatment to prevent bleeds in addition to infusing treatment after bleeds occur.

Bill Garten of Mission, Texas, participated in a Baxter Phase II trial that found that injections of a patient’s own CD34+ stem cells reduced chest pain and improved exercise ability in patients with severe angina due to chronic myocardial ischemia.


10

Teeramanas Tanaekakarapong of Bangkok, Thailand, has had end-stage

kidney disease since 2007. He relies on Baxter peritoneal dialysis

products to maintain his normal day-to-day work and leisure activities.


11

Medical Products

Baxter’s Medical Products business manufactures products used

in the delivery of fluids and drugs to patients. These include

intravenous (IV) solutions and administration sets, premixed drugs

and drug-reconstitution systems, pre-filled vials and syringes

for injectable drugs, IV nutrition products, infusion pumps, and

inhalation anesthetics. The business also is a leader in home-

based renal therapies, such as peritoneal dialysis, and offers other

products and services for people with end-stage kidney disease.

In 1931, Baxter introduced the first commercially produced IV

solutions, premixed in glass containers and shipped ready for use.

Baxter later introduced the world’s first flexible, plastic IV containers

and became the first company to partner with pharmaceutical firms

to premix their drugs in IV solutions for safe and efficient delivery

to patients. In recent years, Baxter’s expertise in medication

delivery has extended to IV nutrition products, infusion pumps

and inhalation anesthetics. In renal therapy, Baxter introduced the

first commercially built artificial kidney in 1956, making life-saving

dialysis possible for people with end-stage kidney disease, and

later helped commercialize peritoneal dialysis, the first home-based

dialysis therapy.


12

Fluid SystemsBaxter is the world’s leading provider of commercially prepared IV solutions as well as frozen and ready-to-use premixed drugs in flexible IV containers. Baxter’s portfolio of IV solutions and premixed drugs is the broadest in the industry. The company also provides IV infusion pumps and administration sets, which control the delivery of IV fluids and drugs to patients.

Specialty PharmaceuticalsBaxter is a leading developer of products for parenteral, or IV, nutrition, which provides life-sustaining support for patients who cannot receive adequate nutrients orally or through other means. Baxter offers one of the broadest portfolios of parenteral nutrition, including solutions, container systems, admixing technologies, vitamins

and mineral formulas. The company also is a leader in anesthesia and sells the three most commonly used modern inhaled anesthetics for general anesthesia. Baxter’s Specialty Pharmaceuticals portfolio includes a short-acting, cardioselective-adrenergic blocker (beta blocker) used to control heart rate in patients who are at high risk for cardiac events during and after surgery.

RenalBaxter is also a leading developer of products for peritoneal dialysis (PD), a home-based therapy for people with end-stage kidney disease. Products include PD solutions, automated cyclers, connectivity devices and ancillary supplies. In addition, the company distributes products for hemodialysis (HD), which generally takes place in a hospital or clinic, and is developing a home HD

Until receiving a kidney transplant, Jim McFarlin of Champaign, Illinois, used automated peritoneal dialysis products from Baxter to cleanse his blood of toxins and waste normally removed by healthy kidneys.

Medical Products


13

platform, which will provide another option for dialysis patients. Baxter also provides products for continuous renal replacement therapy, typically performed in the intensive care unit of a hospital, to treat acute renal failure.

BioPharma SolutionsBaxter advances the clinical and commercial development of innovative drug and drug formulation technologies through contract manufacturing. Products include prefilled injectable drugs in vials and syringes, lyophilized drugs, and biologics such as proteins and antibodies for biotechnology and pharmaceutical companies.

Nurse Heather Evans of Southlake Regional Health Centre in Newmarket, Ontario, Canada, administers parenteral nutrition using one of Baxter’s triple-chamber container systems.

Pharmacy technician Sophia Hohenberg uses a Baxter compounder to custom mix parenteral nutrition solutions at Children’s Mercy Hospital and Clinic in Kansas City, Missouri.

Baxter’s Medical Products

business manufactures products

used in the delivery of fluids and

drugs to patients. In recent years,

Baxter’s expertise in medication

delivery has extended to IV

nutrition products, infusion pumps

and inhalation anesthetics.


14

48,500C O R P O R A T E H E A D Q U A R T E R S

Deerfield, Illinois, USA

APPROXIMATELY

1931employeesworldwide

Est

ablis

hed

2011SALES$13.89 billion

Baxter Facts in Brief

Businesses: BioScience, Medical Products

BAXTER PRODUCTS ARE USED IN:

Hospitals / Surgery centers and other outpatient clinics / Kidney dialysis centers / Doctors’ offices / Nursing homes / Rehabilitation centers / Clinical and medical research laboratories / At home under physician supervision /

2011Sales by Region

(millions)

$1,685

$5,709

$4,392

$2,107

United States

Latin Americaand Canada

Asia-Pacific

Europe


15

MANUFACTURING

Baxter manufactures products in 27 countries:

Australia

Austria

Belgium

Brazil

Canada

Chile

China

Colombia

Costa Rica

Czech Republic

Germany

India

Ireland

Italy

Japan

Malta

Mexico

Philippines

Poland

Saudi Arabia

Singapore

Spain

Switzerland

Tunisia

Turkey

United Kingdom

United States, including Puerto Rico

RESEARCH AND DEVELOPMENT

Research and development (R&D) is essential to

Baxter’s growth. These activities are performed at

R&D centers around the world, including facilities in

Austria, Belgium, Japan and the United States, as

well as in conjunction with select R&D partners.

2011 R&D Investment: $946 million

SustainabilityBaxter has been recognized by many sustainability-related

organizations. In 2011, Baxter was named:

• totheDowJonesSustainabilityIndexforthe13thstraightyear,

and the Medical Products leader for the 10th time

• oneoftheGlobal100MostSustainableCorporationsbyCorporate

Knights Inc.

• toFortunemagazine’slistoftheWorld’sMostAdmiredCompanies

• fourthoverallinNewsweekmagazine’s“GreenRankings”ofthe500

largest U.S. companies, and first globally in the healthcare category

• tothe100BestCorporateCitizenslistbyCorporateResponsibilitymagazineBaxter is a registered trademark of Baxter International Inc.

OperationsBaxter has operations (including offices and manufacturing/

distribution facilities) in 62 countries. The company

conducts business in more than 100 countries.


16

1939First sterile blood-collection container

1956First commercially built artificial kidney

1968First commercially produced factor VIII concentrate to treat hemophilia

1978First ambulatory dialysis system

1979First automated blood-cell separator

1982First heat-treated factor VIII, reducing risk of viral transmission

1998First triple-chamber container system for parenteral nutrition

1941First plasma-collection and storage unit

1959First flexible, plastic blood-collection system

1988First factor VIII purified by chemical and monoclonal techniques

1991First needle-less system for IV therapy

1992First recombinant factor VIII

2007First needle-less IV connector with an antimicrobial coating

2011First triple-chamber container system for parenteral nutrition designed specifically for pediatric patients

1971First flexible, plastic IV container

2003First recombinant factor VIII made without any added human or animal proteins

2005First albumin in a flexible, plastic container

2009First cell culture-based pandemic influenza vaccine

1974First premixed IV drugs

1977First therapy for people with hemophilia who develop antibodies against clotting factor

Baxter History of Firsts

1931First commercially manufactured IV solutions


Des

ign:

par

agra

phs.

com

© Baxter International Inc., 2012. All rights reserved. References in this report to Baxter are intended to refer collectively to Baxter International Inc. and its U.S. and international subsidiaries.


Baxter International Inc.One Baxter ParkwayDeerfield, Illinois 60015-4625USA

www.baxter.com

Regional Headquarters Locations

Europe, Middle East and AfricaBaxter Healthcare SAP.O. BoxCH-8010 ZürichSwitzerland

Asia PacificBaxter (China) Investment Co. Ltd.10F Platinum Tower233 Tai Cang RoadShanghai, 200020China

Latin America/CanadaBaxter Export Corporation101 Northeast 3rd Avenue, Suite 1600Fort Lauderdale, FL 33301-1181USA

Printed on recycled paper containing 10% post-consumer recovered fiber using soy-based inks.


Baxter International Inc. · Baxter is a leading provider of immunoglobulin therapies for patients...

Documents

Transcript of Baxter International Inc. · Baxter is a leading provider of immunoglobulin therapies for patients...